GlaxoSmithKline Debt to Equity Ratio 2006-2018 | GSK

Current and historical debt to equity ratio values for GlaxoSmithKline (GSK) over the last 10 years.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.973B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $342.875B 16.39
Pfizer (PFE) United States $224.185B 13.80
Novartis AG (NVS) Switzerland $187.621B 16.09
Merck (MRK) United States $169.698B 15.17
AbbVie (ABBV) United States $149.801B 15.27
Novo Nordisk (NVO) Denmark $122.714B 20.33
Sanofi (SNY) France $105.515B 13.36
Eli Lilly (LLY) United States $97.721B 19.40
AstraZeneca (AZN) United Kingdom $94.553B 9.90
Bristol-Myers Squibb (BMY) United States $92.973B 18.29